Methypro-NT Tablet SR is a sustained-release formulation combining Pregabalin 75 mg and Nortriptyline 10 mg, designed for the management of neuropathic pain and certain chronic pain conditions. Pregabalin, an anticonvulsant agent, modulates calcium channels in the central nervous system, thereby reducing neurotransmitter release and alleviating neuropathic pain symptoms. Nortriptyline, a tricyclic antidepressant, enhances noradrenergic and serotonergic activity by inhibiting the reuptake of these neurotransmitters, contributing to analgesic effects and mood stabilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting consistent plasma levels and improved patient compliance by reducing dosing frequency. Methypro-NT is indicated for conditions such as diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia, where conventional analgesics may be insufficient. It should be used under medical supervision, with dosage adjustments based on therapeutic response and tolerability. Common adverse effects may include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiac arrhythmias, renal impairment, or concomitant use of CNS depressants. Methypro-NT should not be abruptly discontinued to avoid withdrawal symptoms. Regular monitoring and adherence to prescribed dosing are essential for optimal therapeutic outcomes.